What is Aignostics?
Aignostics operates as an international, interdisciplinary team dedicated to powering the next generation of precision medicine. By integrating artificial intelligence with pathology, the company aims to revolutionize diagnostic capabilities and therapeutic strategies. Their focus on AI and pathology positions them to address critical needs in personalized healthcare, enabling more accurate diagnoses and tailored treatment plans for patients. The company's commitment to innovation in these advanced fields is a key driver of its strategic importance in the evolving medical sector.
How much funding has Aignostics raised?
Aignostics has raised a total of $48M across 2 funding rounds:
Series A
$14M
Series B
$34M
Series A (2022): $14M with participation from Boehringer Ingelheim Venture Fund, High-Tech Gründerfonds, Wellington Partners, and VC Fonds Technologie
Series B (2024): $34M led by CARMA FUND Management, Boehringer Ingelheim Venture Fund, IBB Ventures, Wellington Partners, Mayo Clinic, and ATHOS Holding
Key Investors in Aignostics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund invests in pioneering science aimed at redefining care standards and developing new medicines for patients. The fund focuses on first-in-class, disease-modifying therapeutics across various modalities.
Wellington Partners
Wellington Partners is a leading European venture capital firm that invests in early- and growth-stage life science companies across various sectors, including therapeutics, medical devices, diagnostics, digital health, and industrial biotechnology.
ATHOS Holding
ATHOS Holding GmbH is a company that operates in the Holding Companies industry. It employs 1000to4999 people and has 250Mto500M of revenue.
What's next for Aignostics?
With the recent infusion of $34M in a major strategic investment, Aignostics is poised for accelerated growth and expansion. This substantial backing, following its Series A financing, suggests the company is entering a critical scaling phase. The capital is likely to be deployed towards enhancing its AI-driven pathology platform, expanding its research and development initiatives, and potentially broadening its market reach. Strategic partnerships, such as those with major healthcare entities, will be crucial in translating technological advancements into clinical applications and solidifying Aignostics' position as a leader in precision medicine.
See full Aignostics company page
